JPH05503940A - 新規インスリン組成物 - Google Patents

新規インスリン組成物

Info

Publication number
JPH05503940A
JPH05503940A JP3504590A JP50459091A JPH05503940A JP H05503940 A JPH05503940 A JP H05503940A JP 3504590 A JP3504590 A JP 3504590A JP 50459091 A JP50459091 A JP 50459091A JP H05503940 A JPH05503940 A JP H05503940A
Authority
JP
Japan
Prior art keywords
insulin
ins
general formula
pharmaceutical composition
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP3504590A
Other languages
English (en)
Japanese (ja)
Inventor
ハンセン，ヨルゲン　フレデリク
リベル―マドセン，ウルラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of JPH05503940A publication Critical patent/JPH05503940A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Chairs For Special Purposes, Such As Reclining Chairs (AREA)
  • Medicinal Preparation (AREA)
JP3504590A 1990-02-21 1991-02-21 新規インスリン組成物 Pending JPH05503940A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK0455/90 1990-02-21
DK045590A DK45590D0 (enExample) 1990-02-21 1990-02-21

Publications (1)

Publication Number Publication Date
JPH05503940A true JPH05503940A (ja) 1993-06-24

Family

ID=8093754

Family Applications (1)

Application Number Title Priority Date Filing Date
JP3504590A Pending JPH05503940A (ja) 1990-02-21 1991-02-21 新規インスリン組成物

Country Status (12)

Country Link
EP (1) EP0516704B1 (enExample)
JP (1) JPH05503940A (enExample)
AU (1) AU641991B2 (enExample)
CA (1) CA2075982A1 (enExample)
DE (1) DE69100626D1 (enExample)
DK (1) DK45590D0 (enExample)
HU (1) HUT63858A (enExample)
IE (1) IE910579A1 (enExample)
NZ (1) NZ237176A (enExample)
PT (1) PT96841A (enExample)
WO (1) WO1991012817A1 (enExample)
ZA (1) ZA911279B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9316895D0 (en) * 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
US6342225B1 (en) 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
US6011007A (en) * 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
UA45321C2 (uk) * 1993-09-17 2002-04-15 Ново Нордіск А/С Похідне інсуліну, фармацевтична композиція для лікування діабету та спосіб лікування діабету
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
US6451762B1 (en) 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
CN101955527B (zh) 2003-08-05 2016-04-20 诺沃挪第克公司 新型胰岛素衍生物
JP4463814B2 (ja) 2003-08-05 2010-05-19 ノボ ノルディスク アクティーゼルスカブ 新規のインスリン誘導体
EP1846446B1 (en) 2005-02-02 2013-06-26 Novo Nordisk A/S Insulin derivatives
EP1969004B1 (en) 2005-12-28 2011-08-10 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
JP5550338B2 (ja) 2006-07-31 2014-07-16 ノボ・ノルデイスク・エー／エス ペグ化持続型インスリン
WO2008034881A1 (en) 2006-09-22 2008-03-27 Novo Nordisk A/S Protease resistant insulin analogues
US9387176B2 (en) 2007-04-30 2016-07-12 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
ES2744384T3 (es) 2007-06-13 2020-02-24 Novo Nordisk As Formulación farmacéutica que comprende un derivado de insulina
CN101970477B (zh) 2008-03-14 2014-12-31 诺沃-诺迪斯克有限公司 蛋白酶稳定的胰岛素类似物
PL2254906T3 (pl) 2008-03-18 2017-04-28 Novo Nordisk A/S Stabilizowane względem proteaz, acylowane analogi insuliny
BRPI0919946A2 (pt) 2008-10-30 2016-02-16 Novo Nordisk As tratamento de diabetes melito usando injeções de insulina com frequência de injeção menor que diariamente
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
EP2836508B1 (en) 2012-04-11 2016-06-29 Novo Nordisk A/S Insulin formulations
WO2014177623A1 (en) 2013-04-30 2014-11-06 Novo Nordisk A/S Novel administration regime
HRP20180468T1 (hr) 2013-10-07 2018-05-04 Novo Nordisk A/S Novi derivat analoga inzulina
MY194504A (en) 2016-12-16 2022-11-30 Novo Nordisk As Insulin containing pharmaceutical compositions
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
WO2021009027A1 (en) 2019-07-12 2021-01-21 Novo Nordisk A/S High concentration insulin formulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE971500C (de) * 1950-11-22 1959-02-05 Organon Nv Verfahren zur Herstellung von Insulin-Suspensionen mit verlaengerter Wirkung
DE1107374B (de) * 1958-01-31 1961-05-25 Organon Nv Verfahren zur Herstellung eines Insulin-Praeparates

Also Published As

Publication number Publication date
AU7337891A (en) 1991-09-18
ZA911279B (en) 1991-10-30
IE910579A1 (en) 1991-08-28
EP0516704B1 (en) 1993-11-10
DK45590D0 (enExample) 1990-02-21
AU641991B2 (en) 1993-10-07
DE69100626D1 (de) 1993-12-16
WO1991012817A1 (en) 1991-09-05
NZ237176A (en) 1991-12-23
HUT63858A (en) 1993-10-28
CA2075982A1 (en) 1991-08-22
PT96841A (pt) 1991-11-29
HU9202721D0 (en) 1992-12-28
EP0516704A1 (en) 1992-12-09

Similar Documents

Publication Publication Date Title
JPH05503940A (ja) 新規インスリン組成物
DE3885317T2 (de) Makromolekulare Platin-Antitumorverbindungen.
DE69815877T2 (de) Aggregate von menschlichen insulinderivaten
DE3880346T2 (de) Insulinderivate.
JP4044140B2 (ja) インスリン誘導体類とその使用
EP1274459B1 (en) Sustained release formulations comprising growth hormone
AU621648B2 (en) Pharmaceutical formulation for the treatment of diabetes mellitus
HU227992B1 (en) Interferon conjugates, process for prepairing them, pharmaceutical compositions, containing them and use of them
KR890004687B1 (ko) 생물학적 활성 서방출성 조성물
AU2001259111A1 (en) Sustained release formulations comprising growth hormone
JPH03500286A (ja) 安定なインターフェロン複合体
CH649922A5 (de) Stabilisierte insulinloesungen.
HUT67853A (en) Insulin formulation
KR19990081979A (ko) 개선된 정맥 투여용 농축 주사액 및 주입액
DE3789432T2 (de) Hochmolekulare Verbindung, bestehend aus einer Einheit einer zum Asialoglykoproteinakzeptor leitenden Verbindung und aus einer Einheit einer chelatformenden, an dieser chemisch gebundenen, Verbindung, und ihre Verwendung.
JPH10511365A (ja) 遅延性ｇｌｐ−１組成物
ZA200600846B (en) Novel insulin derivatives
CA1335924C (en) Mixed crystals of insulin and insulin derivatives, a process for the preparation of these mixed crystals, pharmaceutical agents containing these mixed crystals, and the use thereof for the treatment of diabetes mellitus
JP2003504395A (ja) 腎臓に有害な可能性のある分子の腎臓取り込みの阻害
DE1518057C3 (de) Injizierbares adrenocorticotropes Hormonpräparat mit prolongierter ACTH-Aktivität
EP0458939B1 (de) t-PA pro STABILISIERUNG
JPH03206040A (ja) 注射用溶液及びその調製方法
EP1620072B1 (en) Zinc-containing sustained-release composition, its preparation, and method for producing the same
JPH09124512A (ja) 肝臓ターゲティングのための水溶性の薬物−プルラン結合体製剤
JP2002080395A (ja) 心筋傷害処置剤